Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

被引:8292
作者
Sorlie, T
Perou, CM
Tibshirani, R
Aas, T
Geisler, S
Johnsen, H
Hastie, T
Eisen, MB
van de Rijn, M
Jeffrey, SS
Thorsen, T
Quist, H
Matese, JC
Brown, PO
Botstein, D
Lonning, PE
Borresen-Dale, AL [1 ]
机构
[1] Norwegian Radium Hosp, Dept Genet, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Dept Surg, N-0310 Oslo, Norway
[3] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA
[5] Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA
[6] Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA
[7] Stanford Univ, Sch Med, Dept Surg, Stanford, CA 94305 USA
[8] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA
[9] Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA
[10] Stanford Univ, Sch Med, Dept Hlth Res & Policy & Stat, Stanford, CA 94305 USA
[11] Haukeland Univ Hosp, Dept Med, Sect Oncol, N-5021 Bergen, Norway
[12] Haukeland Univ Hosp, Dept Surg, N-5021 Bergen, Norway
[13] Haukeland Univ Hosp, Dept Biochem Endocrinol, N-5021 Bergen, Norway
[14] Lawrence Orlando Berkeley Natl Labs, Div Life Sci, Berkeley, CA 94720 USA
[15] Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA
关键词
D O I
10.1073/pnas.191367098
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The purpose of this study was to classify breast carcinomas based on variations in gene expression patterns derived from cDNA microarrays and to correlate tumor characteristics to clinical outcome. A total of 85 cDNA microarray experiments representing 78 cancers, three fibroadenomas, and four normal breast tissues were analyzed by hierarchical clustering. As reported previously, the cancers could be classified into a basal epithelial-like group, an ERBB2-overexpressing group and a normal breast-like group based on variations in gene expression. A novel finding was that the previously characterized luminal epithelial/estrogen receptor-positive group could be divided into at least two subgroups, each with a distinctive expression profile. These subtypes proved to be reasonably robust by clustering using two different gene sets: first, a set of 456 cDNA clones previously selected to reflect intrinsic properties of the tumors and, second, a gene set that highly correlated with patient outcome. Survival analyses on a subcohort of patients with locally advanced breast cancer uniformly treated in a prospective study showed significantly different outcomes for the patients belonging to the various groups, including a poor prognosis for the basal-like subtype and a significant difference in outcome for the two estrogen receptor-positive groups.
引用
收藏
页码:10869 / 10874
页数:6
相关论文
共 23 条
[1]   Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].
Aas, T ;
Borresen, AL ;
Geisler, S ;
SmithSorensen, B ;
Johnsen, H ;
Varhaug, JE ;
Akslen, LA ;
Lonning, PE .
NATURE MEDICINE, 1996, 2 (07) :811-814
[2]   Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling [J].
Alizadeh, AA ;
Eisen, MB ;
Davis, RE ;
Ma, C ;
Lossos, IS ;
Rosenwald, A ;
Boldrick, JG ;
Sabet, H ;
Tran, T ;
Yu, X ;
Powell, JI ;
Yang, LM ;
Marti, GE ;
Moore, T ;
Hudson, J ;
Lu, LS ;
Lewis, DB ;
Tibshirani, R ;
Sherlock, G ;
Chan, WC ;
Greiner, TC ;
Weisenburger, DD ;
Armitage, JO ;
Warnke, R ;
Levy, R ;
Wilson, W ;
Grever, MR ;
Byrd, JC ;
Botstein, D ;
Brown, PO ;
Staudt, LM .
NATURE, 2000, 403 (6769) :503-511
[3]   EPIDERMAL GROWTH-FACTOR RECEPTOR IN HUMAN-BREAST CANCER - CORRELATION WITH STEROID-HORMONE RECEPTORS AND AXILLARY LYMPH-NODE INVOLVEMENT [J].
BATTAGLIA, F ;
SCAMBIA, G ;
ROSSI, S ;
PANICI, PB ;
BELLANTONE, R ;
POLIZZI, G ;
QUERZOLI, P ;
NEGRINI, R ;
IACOBELLI, S ;
CRUCITTI, F ;
MANCUSO, S .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1988, 24 (11) :1685-1690
[4]   COMPLETE SEQUENCING OF THE P53 GENE PROVIDES PROGNOSTIC INFORMATION IN BREAST-CANCER PATIENTS, PARTICULARLY IN RELATION TO ADJUVANT SYSTEMIC THERAPY AND RADIOTHERAPY [J].
BERGH, J ;
NORBERG, T ;
SJOGREN, S ;
LINDGREN, A ;
HOLMBERG, L .
NATURE MEDICINE, 1995, 1 (10) :1029-1034
[5]  
Berns EMJJ, 2000, CANCER RES, V60, P2155
[6]   TP53 MUTATIONS AND BREAST-CANCER PROGNOSIS - PARTICULARLY POOR SURVIVAL RATES FOR CASES WITH MUTATIONS IN THE ZINC-BINDING DOMAINS [J].
BORRESEN, AL ;
ANDERSEN, TI ;
EYFJORD, JE ;
CORNELIS, RS ;
THORLACIUS, S ;
BORG, A ;
JOHANSSON, U ;
THEILLET, C ;
SCHERNECK, S ;
HARTMAN, S ;
CORNELISSE, CJ ;
HOVIG, E ;
DEVILEE, P .
GENES CHROMOSOMES & CANCER, 1995, 14 (01) :71-75
[7]   Cluster analysis and display of genome-wide expression patterns [J].
Eisen, MB ;
Spellman, PT ;
Brown, PO ;
Botstein, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (25) :14863-14868
[8]   PATHOLOGICAL PROGNOSTIC FACTORS IN BREAST-CANCER .1. THE VALUE OF HISTOLOGICAL GRADE IN BREAST-CANCER - EXPERIENCE FROM A LARGE STUDY WITH LONG-TERM FOLLOW-UP [J].
ELSTON, CW ;
ELLIS, IO .
HISTOPATHOLOGY, 1991, 19 (05) :403-410
[9]  
FISHER ER, 1993, CANCER-AM CANCER SOC, V71, P2141, DOI 10.1002/1097-0142(19930315)71:6+<2141::AID-CNCR2820711603>3.0.CO
[10]  
2-F